Latigo Biotherapeutics, Inc. (LTGO)
NASDAQ: LTGO · Real-Time Price · USD
14.76
+0.76 (5.43%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Company Description
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain.
Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019.
Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Latigo Biotherapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 7, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Nima Farzan |
Contact Details
Address: 1300 Rancho Conejo Boulevard, Suite 305 Thousand Oaks, California 91320 United States | |
| Phone | 805 716 2927 |
| Website | latigobio.com |
Stock Details
| Ticker Symbol | LTGO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2056611 |
| CUSIP Number | 517954103 |
| ISIN Number | US5179541033 |
| Employer ID | 83-2625838 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nima Farzan M.B.A. | Chief Executive Officer, President and Director |
| Neha Krishnamohan | Chief Business Officer and Chief Financial Officer |
| Dr. Neil Kumar Singla M.D. | Chief Medical Officer |
| Julia Chapman | Senior Vice President of Operations |
| Caroline Dougherty | Vice President of Corporate Development |
| Bryan Moyer Ph.D. | Senior Vice President of Discovery |
| Polina German Pharm.D. | Senior Vice President of Clinical Pharmacology and Translational |
| Sabrina Nieder | Vice President and Corporate Controller |
| Vicki Holloway | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 3, 2026 | 10-Q | Quarterly Report |
| Sep 3, 2026 | 8-K | Current Report |
| Aug 18, 2026 | SCHEDULE 13G | Filing |
| Aug 17, 2026 | SCHEDULE 13D | Filing |
| Aug 17, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 7, 2026 | 424B4 | Prospectus |
| Aug 6, 2026 | EFFECT | Notice of Effectiveness |